Galux Seeks Pharma Partnerships at BIO USA as AI Protein Design Moves Toward the Deal Test

As the narrative around AI drug discovery shifts from model presentations to licensing negotiations, the pressure on biotech companies is changing as well. During BIO USA 2026, Korean AI protein design company Galux signaled that it hopes to push its technology toward larger-scale partnerships with global pharmaceutical companies. This is not only a business development itinerary; it also reflects how AI protein design is being asked to enter a stricter phase of industry validation.

Based on currently public information, Galux is focused on using artificial intelligence to help design protein therapeutics and on reaching large pharmaceutical companies through international biotech conferences. Related reports have not disclosed potential deal partners, deal values, indications, or complete experimental data for drug candidates. This news is therefore better understood as an industry signal that partnerships are being advanced, rather than as a completed large-scale licensing deal.

The central question in AI protein design is whether it can identify molecules with specific binding ability, stability, and manufacturability within the vast space of amino acid sequences. If applied to antibodies, bispecific antibodies, or other protein therapies, models may help research teams propose candidate sequences more quickly. But those sequences still must go through cell experiments, protein expression, affinity testing, immunogenicity assessment, and animal studies before they have a chance to move toward human trials.

For large pharmaceutical companies, the appeal of an AI platform does not lie in claims that it can shorten R&D timelines, but in whether it can improve hit rates, reduce the cost of repeated screening, and generate assets that can be incorporated into existing development processes. This also creates a practical threshold for companies such as Galux: the model itself is not the product. What pharmaceutical companies typically accept are reproducible experimental results, clear intellectual property boundaries, and data packages sufficient to support subsequent CMC and regulatory communications.

Background Context

Galux has recently had news that an AI-designed drug candidate received support from a Korean national R&D program, indicating that its technology is moving from early demonstrations toward institutionalized development. Its search for larger-scale international partnerships at BIO USA extends the focus from domestic R&D support to transactions with multinational pharmaceutical companies: the former provides a development track, while the latter requires the company to prove the platform’s value against more market-oriented standards.

This is also a turning point the broader AI drug discovery field is undergoing. In recent years, protein structure prediction and generative models have greatly increased the speed of new molecule design, but clinical success rates have not automatically been rewritten as a result. Especially in protein therapeutics, whether a candidate molecule is easy to produce, whether it triggers unnecessary immune responses in the human body, and whether it can exert therapeutic effects in the correct tissues are often closer to the core of success or failure than model scores.

Therefore, if Galux wants to turn its contacts at BIO USA into deals with global pharmaceutical companies, the key next step will not merely be announcing partnership intentions, but presenting validation data that can withstand external review. AI can accelerate the starting point of design; but the endpoint of drug development is still determined by experimental, clinical, and regulatory evidence.